

Merck invests \$70M for US R&D facility

07 February 2019 | News | By Manbeena Chawla

Expansion of R&D footprint to accelerate science and innovation in Oncology, Immuno-oncology and Immunology globally.



Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, has announced a \$70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts.

The new building will span 145,000 square feet, offering new laboratory and collaborative working space to accommodate approximately 400 new and current R&D employees focused on advancing science in oncology, immuno-oncology and immunology.

With this latest project, Merck KGaA, Darmstadt, Germany will have invested more than \$150 million in infrastructure to advance biopharmaceutical R&D in the state of Massachusetts in recent years, with more than 150 new jobs added to its growing U.S. R&D Hub in Billerica since 2011.

The healthcare business of Merck KGaA, Darmstadt, Germany employs approximately 3,500 R&D professionals across four global R&D hubs: Darmstadt, Germany; Boston, U.S.; Tokyo, Japan; and Beijing, China. Merck KGaA, Darmstadt, Germany invests approximately 20% of total sales in R&D discovery and development each year.